36 results about "Pre osteoblasts" patented technology

The present invention has an object to provide a transplant material allowing systemic bone substance improvement to be realized by cell transplant. The present invention teaches to use a transplant material comprising a cell selected from the group consisting of an embryonic stem cell, a mesenchymal stem cell, an osteoblast cell, a preosteoblast, a chondrocyte and a cell having a capability of bone formation through systemic or topical administration for the improvement in bone quality.

The invention discloses an application of an oligonucleotide compound of micro-RNA (ribonucleic acid) associated with senile osteoporosis. The oligonucleotide compound is used for filling in the gap of micro-RNA based oligonucleotide in application of preparing the compound for promoting osteoblast functions and inhibiting the senile osteoporosis. The technical scheme includes that the micro-RNA associated with the senile osteoporosis is obtained by screening, the oligonucleotide based on the micro-RNA associated with the senile osteoporosis is synthesized and transfected to into preosteoblast and senile osteoporosis mice bodies, results indicate that the osteoblast functions can be promoted, and the progress of the senile osteoporosis is inhibited. The prepared oligonucleotide based on the micro-RNA associated with the senile osteoporosis can inhibit the degree of the senile osteoporosis by promoting the osteoblast functions, and the gap of the micro-RNA based oligonucleotide in application of preparing the compound for promoting the osteoblast functions and inhibiting the senile osteoporosis is filled in.

The invention discloses a shRNA sequence for suppressing mouse MACF1 gene expression and application thereof to solve the technical problem of low efficiency of mouse MACF1 gene expression suppression of the conventional shRNA sequence. The technical scheme is that the shRNA sequence for suppressing mouse MACF1 gene expression is cloned to a pGLV3 lentivirus vector to obtain a recombinant lentivirus vector containing the shRNA sequence, and the recombinant lentivirus vector is used for transfecting a mouse cell to achieve the purpose of suppressing MACF1 gene expression in the cell. The shRNA sequence can remarkably suppress the mRAN expression and protein-level expression of the MACF1 gene in a mouse preosteoblast, and suppresses the functions of proliferation, migration and differentiation of the mouse preosteoblast by suppressing the expression of the MACF1 in the mouse preosteoblast. The shRNA sequence reaches a protein-level suppression ratio above 90% and the gene-level suppression ratio of 81%.

Implant-associated bacterial infections are one of the most serious complications in orthopedic surgery. Treatment of these infections often requires multiple operations, device removal, long-term systemic antibiotics, and extended rehabilitation, and is frequently ineffective, leading to worse clinical outcomes and increased financial costs. Silver nanoparticle/poly(DL-lactic-co-glycolic acid) (PLGA)-coated stainless steel alloy (SNPSA) was evaluated as a potential antimicrobial implant material. It was found that SNPSA exhibited strong antibacterial activity in vitro and ex vivo, and promoted MC3T3-E1 pre-osteoblasts proliferation and maturation in vitro. Furthermore, SNPSA implants induced osteogenesis while suppressing bacterial survival in contaminated rat femoral canals. The results indicate that SNPSA has simultaneous antimicrobial and osteoinductive properties that make it a promising therapeutic material in orthopedic surgery.

The invention discloses application of miR-489-3p to preparation of medicines for diagnosing and treating human osteoporosis. According to the technical scheme, the detection of thighbone tissue samples of elderly patients with osteoporosis shows that miR-489-3p is low in expression in human osteoporosis tissue samples and can be used as a marker gene for diagnosing osteoporosis; an analogue and an antagonist of miR-489-3p are designed and prepared, then the analogue and the antagonist of the miR-489-3p are transfected into mice pre-osteoblasts MC3T3-E1 for carrying out a mineralization-alizarin red s dyeing experiment and an ALP dyeing experiment; technical detection of qPCR and Western blot shows that miR-489-3p can accelerate osteocyte differentiation and also can carry out targeted regulation on non-receptor protein-tyrosine-phosphatase6 (PTPN6) molecules. The application of miR-489-3p to preparation of medicines for diagnosing and treating human osteoporosis shows that miR-489-3p can regulate PTPN6 molecules to be used as target sites of action of medicines for treating skeleton system diseases such as osteoporosis.

The invention discloses a preparation method for a facilitation bone titanium tantalum composite. According to the technical scheme, titanium powder and tantalum powder are subjected to ball milling and mixing, then discharge plasma sintering is conducted, polishing is conducted, and the facilitation bone titanium tantalum composite is obtained, has biocompatibility, does not have cytotoxicity, does not influence cell proliferation, and has good induction effect on osteogenic differentiation of preosteoblasts; and meanwhile alkali-heat-treatment is conducted on the titanium tantalum composite,rubidium is mixed into the surface of the titanium tantalum composite, bioactivity of the titanium tantalum composite can be further promoted, and the preosteoblasts are further facilitated and induced to differentiate to osteoblasts. If before alkali-heat-treatment, sand blasting treatment and acid treatment are conducted first, facilitation bone ability of the obtained facilitation bone titanium tantalum composite is more excellent.

Human osteogenic cells secrete biological activities that stimulate cancer cells to migrate to and/or invade tissues. Conditioned medium (CM) produced by human pre-osteoblasts and osteoblasts induced migration and tissue invasion of human prostate cancer cells. Thus, conditioned media and/or proteins isolated therefrom may be used to identify metastasis-inducing factors. Also described are methods of identifying an inhibitor of such factors.

The invention relates to a surface rubidium-doped titanium material as well as a preparation method and application thereof. The preparation method comprises the following steps: cleaning a titanium material after alkali hot treatment to be neutral, drying, then soaking in a rubidium salt solution for reaction and obtaining a titanium material after rubidium salt treatment; calcining the titaniummaterial after rubidium salt treatment at a temperature of 500-750 DEG C to obtain the surface rubidium-doped titanium material; in the rubidium salt solution, the concentration of rubidium ions is 1-10 mol/L. The surface rubidium-doped titanium material provided by the invention has a staphylococcus aureus growth resistance function, is good in biocompatibility and free from cytotoxicity, does not affect the cell proliferation and has a good effect on inducing osteoblastic differentiation of preosteoblasts. The material has antibacterial property and biocompatibility and can effectively solvewound infection and other problems when the titanium material is clinically applied, thereby having a wide application prospect in clinical bone repair.

The invention relates to a BMP-2 activator and application of the same in stem cell induced differentiation. Alkaline phosphatases (ALPs), early osteogenesis markers, are mainly distributed in cytomembranes to promote cell calcification, quantitative detection of the ALPs can reflect the differentiation level of osteoblasts, and the higher the activity is, the more obvious differentiation of preosteoblasts into the mature osteoblasts is; the high expression of the ALP activity is an early indicator for osteogenic differentiation maturation, bone formation is enhanced when the ALP activity is improved, and bone matrix mineralization is promoted, so that the ALP activity is a good indicator reflecting the differentiation degree and the functional status of the osteoblasts; to-be-tested compounds 1-3 promote osteogenic differentiation of hBMSCs by activating BMP-2 protein expression in the hBMSCs, and to-be-tested compounds 4 and 5 promote osteogenic differentiation of the hBMSCs by activating VEGF165 protein expression in the hBMSCs.

The present invention relates to novel immortalized pre-osteoblast cell lines derived from the periost and capable of differentiate to osteoblasts. In particular, the present invention pertains to the use of such cell lines in assays for detecting substances controlling the differentiation of pre-osteoblasts to osteoblasts and for detecting substances enabling improved bone formation, maintenance of bone mass, bone repair and for preventing the onset of osteoporosis.

The invention relates to vascular endothelial growth factor 165 activators and application of the same to stem cells. Alkaline phosphatase (ALP) is an early osteogenesis marker, is mainly distributedin cell membranes and can promote cell calcification. Quantitative detection of ALP can reflect the differentiation level of osteoblasts. The higher the activity of ALP is, the more obvious the differentiation of preosteoblasts into mature osteoblasts is. The high expression of ALP activity is an early indicator for the differentiation and maturation of osteoblasts. When ALP activity is enhanced,bone formation is improved and bone matrix mineralization formation is promoted. Therefore, ALP activity is a good indicator reflecting the differentiation degree and functional status of osteoblasts.To-be-tested compounds 1 to 3 promote the osteogenic differentiation of hBMSCs by activating BMP-2 protein expression in hBMSCs; and to-be-tested compounds 4 and 5 promote the osteogenic differentiation of hBMSCs by activating VEGF-165 protein expression in hBMSCs.

The present invention relates to a pharmaceutical composition for preventing or treating a bone-related disease; and the pharmaceutical composition is very effective in preventing or treating bone-related diseases in that it not only promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated. In addition, the present invention relates to a pharmaceutical composition for preventing or treating a menopausal disease, in particular, a menopausal bone disease; and the pharmaceutical composition is very effective in preventing or treating a menopausal bone-related disease in that it not only increases the volume of trabecular bone and promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated.

The invention discloses a multifunctional titanium alloy coating and a preparation method and application thereof. The preparation method comprises the following steps: depositing graphene (GO) and berberine on the surface of a pure titanium metal sheet by adopting a cathode electrophoretic deposition technology to prepare a titanium alloy coating Beramp; gO (at) Ti has no obvious cytotoxicity, and an in-vitro osteogenesis activity evaluation result shows that compared with a Ti group, Beramp, GO (at) Ti and GO (at) Ti have no obvious cytotoxicity; and the preosteoblasts on the GO (at) Ti group show higher expression of osteogenesis-related genes. Meanwhile, bacterial proliferation and plate coating results show that Beramp; and the GO (at) Ti group has excellent antibacterial performance through the synergistic effect of GO and berberine. In-vitro experiments also show that the material has good antibacterial effect and biocompatibility, and shows huge potential in surgical implants.

The invention discloses a metal stent filled with a magnetic composite material, the metal stent is composed of a magnetic composite material and a three-dimensional porous metal stent, the magnetic composite material is formed by nano magnetic particles, gelatin and hydroxyapatite powder, and the metal stent is filled with the magnetic composite material. The mass ratio of the hydroxyapatite powder to the gelatin to the nano magnetic particles in the magnetic composite material is 1: 1: (0.1-1). According to the invention, two bone matrix main components (collagen and nano-hydroxyapatite) are adopted, and a degradable bionic three-dimensional micro-scaffold is built in each hole of porous titanium; meanwhile, nano magnetic particles and a static magnetic field are introduced to promote angiogenesis and stimulate differentiation of preosteoblasts to osteoblasts and deposition of extracellular matrixes, so that an optimal proliferation and differentiation environment is provided for bone formation related cells.

The present invention relates to a bone morphogenetic protein 2 activator for promoting directed differentiation of stem cells. Alkaline phosphatase (ALP) is an early osteogenesis marker, and is mainly distributed in cell membranes to promote cell calcification. The quantitative detection of the ALP can reflect the differentiation level of osteoblasts. If the activity of the ALP is higher, the higher activity of the ALP indicates that pre-osteoblasts have more obvious differentiation tendency to mature osteoblasts. The high expression of the activity of the ALP is an early marker of osteoblastdifferentiation and maturation. When the activity of the ALP is enhanced, bone formation is enhanced, and bone matrix mineralization is promoted. Therefore, the activity of the ALP is a good indicator for reflecting the degree differentiation and the functional status of the osteoblasts. The osteogenic differentiation of hBMSCs can be promoted by activating BMP-2 protein expression in the hBMSCsby to-be-tested compounds 1 to 3. The osteogenic differentiation of the hBMSCs can be promoted by activating VEGF-165 protein expression in the hBMSCs by to-be-tested compounds 4 and 5.

The invention discloses a method for inducing bone mesenchymal stem cells to osteoblast differentiation. A crystal face single crystal surface of strontium titanate {100} is irradiated with ultraviolet light firstly to produce a surface with specific hydroxyl properties, then bone mesenchymal stem cells are cultured on the surface, preosteoblasts can be obtained after the culturing for 7 days by using the conventional DMEM basal medium, and mature differentiation osteoblasts can be obtained after the culturing for 14 days. The method for inducing directional differentiation of the stem cells by utilizing hydroxyl properties of the material surface, provided by the invention, is simple and convenient to operate and very low in cost, can obviously improve the differentiation ratio of the mesenchymal stem cells into the osteoblasts, and further can avoid application risks and immunogenicity of animal serums and biochemical reagents, thereby being applicable to the fields of bone tissue repair, reconstruction and the like.